BOSTON THERAPEUTICS, INC. (OTCMKTS:BTHE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Agreements of Certain Officers
BOSTON THERAPEUTICS, INC. (OTCMKTS:BTHE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On November 14, 2016, Alan M. Hoberman, Ph.D. provided Boston Therapeutics, Inc. (the “Company). with a letter of resignation dated September 15, 2016, to which Mr. Hoberman resigned as a director of the Company.
About BOSTON THERAPEUTICS, INC. (OTCMKTS:BTHE)
Boston Therapeutics, Inc. (BTI) is a pre-clinical and clinical-stage pharmaceutical company. The Company is focused on the development, manufacture and commercialization of carbohydrate-based therapeutic drugs and dietary supplements designed to address blood sugar management and inflammatory diseases. BTI-320 is its lead product candidate. BTI-320 is a Carbohydrate hydrolyzing Enzyme Inhibitor for treatment of patients with Type 2 diabetes. BTI-320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications, which is designed to reduce post-meal glucose elevation. BTI-320 is in Phase II clinical development. IPOXYN and OXYFEX are in pre-clinical stage of drug development. IPOXYN is indicated for lower limb vascular complications of diabetes. OXYFEX is indicated for veterinary ischemic tissue. It produces and sells SUGARDOWN, a non-systemic carbohydrate-based dietary food supplement to support post-meal blood glucose. BOSTON THERAPEUTICS, INC. (OTCMKTS:BTHE) Recent Trading Information
BOSTON THERAPEUTICS, INC. (OTCMKTS:BTHE) closed its last trading session 00.0000 at 0.0700 with – shares trading hands.
Boston Therapeutics, Inc. (BTI) is a pre-clinical and clinical-stage pharmaceutical company. The Company is focused on the development, manufacture and commercialization of carbohydrate-based therapeutic drugs and dietary supplements designed to address blood sugar management and inflammatory diseases. BTI-320 is its lead product candidate. BTI-320 is a Carbohydrate hydrolyzing Enzyme Inhibitor for treatment of patients with Type 2 diabetes. BTI-320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications, which is designed to reduce post-meal glucose elevation. BTI-320 is in Phase II clinical development. IPOXYN and OXYFEX are in pre-clinical stage of drug development. IPOXYN is indicated for lower limb vascular complications of diabetes. OXYFEX is indicated for veterinary ischemic tissue. It produces and sells SUGARDOWN, a non-systemic carbohydrate-based dietary food supplement to support post-meal blood glucose. BOSTON THERAPEUTICS, INC. (OTCMKTS:BTHE) Recent Trading Information
BOSTON THERAPEUTICS, INC. (OTCMKTS:BTHE) closed its last trading session 00.0000 at 0.0700 with – shares trading hands.
